Latest Breaking News On - Blinded independent central review - Page 1 : vimarsana.com

U S Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors

U S Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Susan spinosaAlexander drilonNick botwoodBristol myers squibbNational cancer instituteDrug administrationExchange commissionBristol myers squibb companyEuropean society for medical oncologyEarly drug development serviceMemorial sloan kettering cancerImportant safety informationMedical oncologyBristol myersBlinded independent central reviewResponse evaluation criteria

U S Food and Drug Administration Approves Augtyrotm (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors

Bristol Myers Squibb today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Augtyrotm (repotrectinib) for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that.

Bristol myers squibbNick botwoodAlexander drilonSusan spinosaDrug administration approves augtyrotmNational cancer instituteBristol myers squibb companyExchange commissionProduct serviceEuropean society for medical oncologyDrug administrationNext generation tyrosine kinase inhibitorPositive locally advancedMetastatic solidMyers squibbEarly drug development service

Pfizer s LORBRENA Study: Majority ALK+ Lung Cancer Patients Live Five Years Disease-Free

Pfizer s LORBRENA Study: Majority ALK+ Lung Cancer Patients Live Five Years Disease-Free
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

South koreaUnited statesKenneth culverRoger danseyDepartment of medical oncologyEuropean unionPeter maccallum cancer centreAmerican society of clinical oncologyPfizer incClinical affairsHazard ratioConfidence intervalClinical oncologyAnnual meetingChief development officerBenjamin solomon

KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer

First presentation of data from Phase 3 KRYSTAL-12 study showed statistically significant and clinically meaningful improvement in progression-free survival with KRAZATI compared to standard of care.

United statesBristol myers squibbTony mokAbderrahim oukessouExchange commissionDepartment of clinical oncologyAmerican society of clinical oncologyMirati therapeutics incChinese university of hong kong cu medicineDrug administrationBlinded independent central reviewClinical oncologyAnnual meetingChinese universityHong kongBristol myers

Pfizer s LORBRENA® CROWN Study Shows Majority of Patients with ALK-Positive Advanced Lung Cancer Living Beyond Five Years Without Disease Progression

An unprecedented 60% of patients remain alive without disease progression after five years Updated results show continued 81% reduction in risk of progression or death and 94% reduction in.

United statesSouth koreaRoger danseyKenneth culverClinical affairsExchange commissionAmerican society of clinical oncologyInternational agency for research on cancerAmerican cancer societyPeter maccallum cancer centreWorld health organizationPfizer incEuropean unionDepartment of medical oncologyHazard ratioConfidence interval